Urbana, Ill. – A new study by Cancer Center at Illinois Education Program Leader, Zeynep Madak-Erdogan and her team, have found a new mechanism of endocrine resistance in breast cancers metastasized to the liver.
Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM 1, a transcription factor that regulates the activity of dozens of genes. The new compounds suppress tumor growth in human cells and in mouse models of several types of human breast cancer.
